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Abstract
Background: Screening for undiagnosed diabetes is not widely undertaken due to the high costs and invasiveness
of blood sampling. Simple non-invasive tools to identify high risk individuals can facilitate screening. The main
objectives of this study are to develop and validate a risk score for screening undiagnosed diabetes among Sri
Lankan adults and to compare its performance with the Cambridge Risk Score (CRS), the Indian Diabetes Risk Score
(IDRS) and three other Asian risk scores.
Methods: Data were available from a representative sample of 4276 adults without diagnosed diabetes. In a
jack-knife approach two thirds of the sample was used for the development of the risk score and the remainder
for the validation. Age, waist circumference, BMI, hypertension, balanitis or vulvitis, family history of diabetes,
gestational diabetes, physical activity and osmotic symptoms were significantly associated with undiagnosed
diabetes (age most to osmotic symptoms least). Individual scores were generated for these factors using the beta
coefficient values obtained in multiple logistic regression. A cut-off value of sum = 31 was determined by ROC
curve analysis.
Results: The area under the ROC curve of the risk score for prevalent diabetes was 0.78 (CI 0.73–0.82). In the
sample 36.3 % were above the cut-off of 31. A risk score above 31 gave a sensitivity, specificity, positive predictive
value and negative predictive value of 77.9, 65.6, 9.4 and 98.3 % respectively. For Sri Lankans the AUC for the CRS
and IDRS were 0.72 and 0.66 repectively.
Conclusions: This simple non-invasive screening tool can identify 80 % of undiagnosed diabetes by selecting 40 %
of Sri Lankan adults for confirmatory blood investigations.
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Background
Diabetes mellitus is increasing worldwide [1]. Type 2
diabetes accounts for over 90 % of prevalent cases in
high risk populations such as South Asians and Pima
Indians [2, 3]. Among those with type 2 diabetes 30 to
76 % remain undiagnosed according to different
estimates [2, 4–7]. In a national level epidemiological
study conducted in 2006 in Sri Lanka, the diabetes
prevalence was reported as 10.3 % with 36 % remaining
undiagnosed [2]. Early diagnosis is important as in the
United Kingdom Prospective Diabetes Study (UKPDS),
37 % of those newly diagnosed with type 2 diabetes had
retinopathy [8]. A cross-sectional study in Sri Lanka
reported 15 % retinopathy and 25 % neuropathy in newly
diagnosed diabetic subjects [9]. These data suggest that
type 2 diabetes may remain undiagnosed for many years
leading to adverse diabetes related outcomes.
Early diagnosis and optimisation of therapy may
improve outcomes in patients with diabetes, as tight
control of blood glucose and blood pressure has been
shown to reduce the incidence of microvascular
complications in type 2 diabetic subjects [10, 11] and
control of lipids reduces macrovascular disease and
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mortality in people with diabetes [12]. This reduction of
risk of microvascular complications, myocardial infarc-
ton and death from any cause persisted in 10 years of
post-trial followup [13]. Since the diagnosis of diabetes
requires invasive blood sampling and laboratory investi-
gations, there is an ongoing debate about the benefit and
the potential harm of screening for diabetes [14–17]. A
recent study from UK has reported limited psychological
impact on patients from screening for diabetes [18]. We
hypothesise that if sensitive, specific and low cost tools
(that are non-invasive) can be developed, large scale
community level diabetes screening can be undertaken
with a potential for the improvement of outcomes in
otherwise undiagnosed people.
Questionnaire based risk screening tools have been
developed for the detection of diabetes in other popula-
tions [16, 19–21]. The aim of this study was to develop
and validate a screening tool for undiagnosed diabetes in
Sri Lanka based on demographic information. The per-
formance of the risk tools developed for White Europeans
in the UK by Griifin et al. [16] and Asian Indians by Rama-
chandran et al. [22] were compared with our risk score.
Methods
Data from 4276 subjects without previously diagnosed
diabetes from the Sri Lanka Diabetes and Cardiovascular
Study (SLDCS) were used for risk score development
and validation. SLDCS was a nationally representative
study conducted in seven out of the nine provinces in
Sri Lanka using a probability cluster-sampling technique.
The study was approved by the Ethical Review Commit-
tee of the Faculty of Medicine – University of Colombo.
Informed written consent was obtained from all partici-
pants. The sampling and data collection of this study
has been reported previously [2]. Two thirds of this
study population were randomly selected for the devel-
opment of the risk score. The remaining third of the
subjects were used for validation.
We used methods adopted for the development of the
Finnish and Cambridge Risk scores [16, 21, 22]. We
performed univariate regression analysis to select vari-
ables that were associated with undiagnosed diabetes.
Variables that could be easily measured in the commu-
nity with minimal expertise and resources were included.
We did not include area of residence, occupation and
income. Multiple logistic regression analysis was carried
out with newly diagnosed diabetes as the dependent
variable and those variables identified from the univari-
ate analyses at significance level <0.05.
The β coefficient values obtained in the logistic regres-
sion analysis (without stepwise elimination) were used to
derive a risk score. The sum of β coefficients in multiple
regression analysis can be used to derive cumulative
regression coefficients [23]. Data were analysed using
SPSS version 14 (SPSS Inc, Chicago IL, USA). Similar
methods have been adopted in the development of the
Finnish and Cambridge Risk scores [16, 21, 22]. The
score was based on the beta coefficient multiplied by a
factor of ten to allow integer scores. The total score was
calculated as the sum of the individual weighted scores.
Diabetes was diagnosed using the 1989 WHO criteria
using fasting and 2-h OGTT plasma glucose [24]. Physical
activity was recorded (all activities including occupational,
daily living and leisure time) using the short format of
International Physical Activity Questionnaire (IPAQ) and
categorised as low, moderate and active according to the
IPAQ categorisation [25]. Hypertension was diagnosed
when systolic blood pressure was ≥140 mmMg/ diastolic
blood pressure ≥90 mmMg or if the subjects were on
antihypertensive medications [26]. Balanitis was defined as
persistent itching or soreness of the glans penis and
vulvitis as persistent itching, soreness and discharge from
the vulva. Frequent thirst, polyuria and nocturia were
considered as osmotic symptoms.
The performance of the risk score in detecting preva-
lent undiagnosed diabetes was evaluated using receiver-
operating characteristic (ROC) curve analysis. The risk
score value with combined highest sensitivity and specifi-
city was considered the optimal cut-off value. The risk
score was validated in the remaining one third of the
population. The performance of the Cambridge Risk Score
(CRS), the Indian Diabetes Risk Score (IDRS), two Chinese
risk scores and a Thai risk score [16, 22, 27–29] when
applied to the Sri Lankan population were compared with
the newly derived risk score (SLDSRISK).
Results
In the 4276 subjects 196 had newly diagnosed diabetes.
Metabolic, anthropometric and lifestyle characteristics are
shown in Table 1. Women had higher mean 2-h plasma
glucose and BMI compared to men (p < 0.001). They also
had higher prevalence of physical inactivity (p < 0.001) and
infections in the genital area compared to men (p < 0.001).
Table 2 compares development and validation cohorts
which shows no significant difference in the two groups
with regard to any of the parameters.
Model development
In 2826 subjects in the development cohort 128 had
newly diagnosed diabetes (46 men and 86 women). The
results of the multiple logistic regression analysis
(without stepwise elimination) and the individual scores
are shown in Table 3. The ROC curve associated with
prevalent undiagnosed diabetes in the model develop-
ment is shown in Fig. 1a. The AUC of the ROC curve
for detecting prevalent undiagnosed diabetes was 78 %.
A cut-off value of 31 had maximal combined sensitivity
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and specificity. The risk score (Sri Lanka Diabetes Risk
Score – SLDRISK) is available as a supplementary file.
Model validation
When we applied SLDRISK to the remaining one third
of the sample (cohort 1450 people, 68 with newly diag-
nosed Type 2 diabetes, 38.9 % had a score above 31
(risk-score positive). The risk score has a sensitivity of
77.9 % and a specificity of 63.0 %. The score has a
positive predictive value (PPV) of 9.4 % and a negative
predictive value (NPV) of 98.3 % for predicting prevalent
diabetes in the remaining one third of the subjects
(Fig. 1a). The ROC curve analysis in the validation
sample showed an AUC of 0.74.
Comparison of SLDRISK with Cambridge, Indian, Chineses
and Thai Diabetes Risk Scores
The AUC of the CRS when applied to the Sri Lanka
sample was 0.66 (0.62–0.71) with the cut-off for optimum
combined sensitivity and specificity being 0.052 (Fig. 1c).
Accordingly, the sensitivity, specificity, PPV and NPV for
the CRS were 54.4, 59.3, 6.2 and 96.4 % (Table 4). The
AUC of the IDRS was 0.72 (0.68–0.76) (Fig. 1d). The
optimal cut-off for the IDRS was 21.5. The sensitivity,
specificity, PPV and NPV of IDRS were 66.2, 66.1, 8.8 and
97.5 % respectively.
Two Chineses risk scores and a Thai risk score were
also applied to the Sri Lanka sample. The optimal cut-
offs for risk scores 1 [27], 2 [28] and 3 [29] were 7.5,
Table 1 Characteristics of the sample according to gender
Male Female All *p value
n
Age (years) 45.5 (15.8) 45.0 (14.5) 45.2 (15.1) 0.363
FPG (mmol/l) 4.9 (1.0) 4.8 (1.2) 4.9 (1.1) 0.375
2-h PG (mmol/l) 5.7 (2.9) 6.4 (2.8) 6.1 (2.8) < 0.001
BMI (kg/m2) 20.9 (3.7) 22.0 (4.5) 21.6 (4.2) < 0.001
Waist circumference (cm) 77.4 (10.8) 76.1 (12.1) 76.6 (11.6) < 0.001
Male sex (%) – – 40.0 –
Physical inactivity (%) 14.5 7.9 10.5 < 0.001
Family history of
diabetes (%)
21.3 24.5 23.2 0.016
Hypertension (%) 24.3 24.5 24.4 0.955
Gestational diabetes (%) 1.2 – –
Osmotic symptoms (%) 14.1 13.6 13.8 0.661
Balanitis or vulvitis (%) 1.1 5.4 3.7 < 0.001
*p value – between male and female
Table 2 Characteristics of the sample according to
development and validation cohort
Development Validation All *p value
n
Age (years) 45.3 (15.1) 45.1 (14.9) 45.2 (15.1) 0.743
FPG (mmol/l) 4.9 (1.1) 4.9 (1.2) 4.9 (1.1) 0.796
2-h PG (mmol/l) 6.1 (2.9) 6.2 (2.8) 6.1 (2.8) 0.796
BMI (kg/m2) 21.6 (4.3) 21.6 (4.2) 21.6 (4.2) 0.815
Waist circumference
(cm)
76.6 (11.8) 76.6 (11.3) 76.6 (11.6) 0.994
Male sex (%) 39.6 40.5 40.0 0.560
Physical inactivity (%) 10.7 10.2 10.5 0.971
Family history of
diabetes (%)
23.3 23.2 23.2 0.971
Hypertension (%) 24.6 24.1 24.4 0.706
Gestational diabetes
(%)
0.7 0.8 0.7 0.979
Osmotic symptoms (%) 13.0 15.4 13.8 0.027
Balanitis or vulvitis (%) 3.6 3.9 3.7 0.677
*p value – between development and validation
Table 3 Multiple logistic regression analysis and individual
scores for variables included in the risk score
Variables









30–39 2.6 (0.9–7.8) 0.95 10
40–49 4.8 (1.7–13.7) 1.57 16




18.5–22.9 1.7 (0.7–3.9) 0.52 5
≥23.0 2.1 (0.8–5.2) 0.72 7
Waist circumference
(cm) (p = 0.000)





1.9 (0.9–4.1) 0.65 7
F≥ 80/M≥
85




Present 2.3 (1.6–3.4) 0.84 8
Family history of
diabetes (p = 0.000)
Present Reference 0
Absent 1.7 (1.1–2.5) 0.52 5
Physical activity






1.2 (0.8–1.8) 0.17 2












Present 1.2 (0.7–1.9) 0.14 1
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27.5 and 6.5 respectively. SLDRISK performed better
than all these other Asian risk scores in predicting
prevalent diabetes in Sri Lankan population (Table 5).
Discussion
In this study we have developed and validated a tool for
community level screening of undiagnosed diabetes in a
high risk South Asian population. The SLDRISK can be
used by local health care workers in a village setting or
in health centres wihtout needing hospital or laboratory
support. It can be used with minimal expertise. The AUC
of 0.78 for the SLDRISK indicated satisfactory predictabil-
ity of prevalent undiagnosed diabetes in Sri Lankan adults.
The score would detect 78 % of those with undiagnosed
diabetes in the community by identifying 39 % of risk
score positive adults in the general population. This non-
Fig. 1 ROC curves for SLDRISK, CRS and IDRS. a and b shows SLDRISK on cohorts 1 and 2 respectively. c shows the CRS on cohort 1.
d shows IDRS on cohort 1
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invasive tool has the potential to be used for targeting
individuals for definitive diabetes diagnostic screening at a
population level.
Many systematic reviews have been done over the
years on diabetic risk scores. Collins et al. reviewed 39
similar studies done before 2011 [30]. Age, Family history
of diabetes, hypertension, BMI and waist circumference
were the most frequenly used risk predictors in those
studies. All these risk predictors are included in our study
as well.
The CRS risk score which showed an AUC of 0.80 for
the White Europeans was less predictive for the Sri
Lankan population (AUC 0.66). The positive predictive
value of CRS for Sri Lankans at an optimal cut-off value
of 0.052 was 6.2 % compared to 9.4 % in the SLDRISK.
The IDRS performed comparable to the SLDRISK in Sri
Lankans (AUC 0.72 vs. 0.78, PPV 8.8 vs. 9.4). This
highlights the importance of using ethnic specific tools
in epidemiology and disease screening. In the SLDRISK
we have used common diabetes symptoms that were not
used in the CRS and the IDRS to increase the sensitivity
of the risk score.
Our projections of diabetes in Sri Lanka indicate a
prevalence of 13.9 % in 2030 [2]. Other countries in
South Asia like India, Pakistan and Bangladesh are also
having high prevalence of diabetes [31–37]. This has
necessitated effective primary and secondary preventive
measures to prevent the rising prevalence as well as
diabetes related adverse health outcomes in this ethnic
group. Therefore, low cost and non-invasive epidemio-
logical tools such as SLDRISK are of particular value in
South Asian countries with limited healthcare resources
and high disease burden.
Conclusions
In conclusion, we have developed and validated a simple,
low-cost and a non-invasive tool for stepwise commu-
nity level screening of undiagnosed diabetes in a high
risk South Asian population in Sri Lanka. Our risk score
is comparable to the one developed for Asian Indians by
Ramachandran et al. and can be used in Sri Lanka and
perhaps among other South Asians for community level
screening programmes for diabetes.
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Table 4 The performance of SLDRISK, CRS and the IDRS in the
Sri Lankan adult population
SLDRISK IDRS CRS
AUC 0.78 0.72 0.66
Sensitivity (%) 77.9 66.2 54.4
Specificity (%) 65.6 66.1 59.3
Positive predictive value (%) 9.4 8.8 6.2
Negative predictive value (%) 98.3 97.5 96.4
Table 5 The performance of SLDRISK compared to two Chinese
risk scores and a Thai risk score in the Sri Lankan adult
population
SLDRISK RS 1 [27] RS 2 [28] RS 3 [29]
AUC 0.78 0.70 0.77 0.76
Sensitivity (%) 77.9 65.5 71.0 62.2
Specificity (%) 65.6 64.9 73.0 69.5
Positive predictive value (%) 9.4 7.7 11.1 8.7
Negative predictive value (%) 98.3 97.6 98.1 97.4
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